Abstract

The present invention relates to a device for obtaining a trained machine learning segmentation model for carotid segmentation using positron emission tomography (PET) images of a patient and to a device and a computer-implemented method for carotid segmentation of positron emission tomography (PET) frames previously acquired on a patient using the trained machine learning segmentation model (31) for carotid segmentation, wherein said segmentation model is configured to provide a segmentation mask of the at least one portion of interest of the carotid arteries.

IPC Classes  ?

• G06T 7/174 - SegmentationEdge detection involving the use of two or more images
• A61B 6/03 - Computed tomography [CT]
• G06T 7/11 - Region-based segmentation

Abstract

The invention relates to a method for detecting a change in a patient's physiological condition with respect to a reference physiological condition. The method is based on a multimodal analysis that involves measurements of electroencephalography signals Si from the patient and at least one other physiological signal SN+1(N≥1) from the patient. Based on these measurements, the invention proposes calculating distances di(m) associated with the electroencephalography measurements and with the measurements of the other physiological signals and fusing these data, the data having previously undergone a certain number of mathematical processing operations. In the context of the invention, the fused data may be assigned a weighting coefficient chosen according to one or more a priori or a posteriori criteria.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/31 - Input circuits therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/369 - Electroencephalography [EEG]
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation

Abstract

The present invention provides compounds able to induce neuroprotection of damaged neurons and boost the remyelination potential of oligodendrocytes. The compounds have been identified through methods of pharmacological screening of a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to the field of medicine. In particular, it relates to the use of tetracycline derivatives in the treatment or prevention of a neurodegenerative or neuroinflammatory disease, such as Parkinson's disease.

IPC Classes  ?

• A61K 31/65 - Tetracyclines
• C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
• C07C 235/84 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to means for transiently disrupting the neurovascular barrier of a human. More particularly, the invention relates to ultrasound contrast agent for use in treating Amyotrophic Lateral Sclerosis (ALS) in a subject, wherein the ultrasound contrast agent is used in combination with ultrasound beam for transiently disrupting the neurovascular barrier of the subject.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 38/30 - Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
• A61N 7/00 - Ultrasound therapy
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Abstract

1N+1N+1 (N ≥ 1) from the patient. Based on these measurements, the invention proposes calculating distances di(m) associated with the electroencephalography measurements and with the measurements of the other physiological signals and fusing these data, the data having previously undergone a certain number of mathematical processing operations. In the context of the invention, the fused data may be assigned a weighting coefficient chosen according to one or more a priori or a posteriori criteria.

IPC Classes  ?

• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• A61B 5/369 - Electroencephalography [EEG]
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to the field of medicine. In particular, the invention relates to tenoxicam and its use in the treatment of proteinopathy of the central nervous system. More specifically, the present invention relates to tenoxicam compound for use in the treatment of an animal or human prion disease.

IPC Classes  ?

• A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to the field of medicine. In particular, it relates to naloxone and its use in the treatment of proteinopathies of the central nervous system, in particular of the animal or human prion disease. The invention also relates to a pharmaceutical combination of naloxone and tenoxicam and its use in the treatment of proteinopathy of the CNS.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention provides compounds able to induce neuroprotection of damaged neurons and boost the remyelination potential of oligodendrocytes. Said compounds have been identified through methods of pharmacological screening on a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.

IPC Classes  ?

• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/415 - 1,2-Diazoles
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/4462 - Non-condensed piperidines, e.g. piperocaine only substituted in position 3
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Abstract

The present invention relates to the field of medicine. In particular, it relates to the use of tetracycline derivatives in the treatment or prevention of a neurodegenerative or neuroinflammatory disease, such as Parkinson's disease.

IPC Classes  ?

• A61K 31/65 - Tetracyclines
• A61P 25/16 - Anti-Parkinson drugs
• C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
• C07C 235/40 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton

Abstract

The invention relates to compounds exhibiting kallikrein inhibitory activity, and to compositions comprising at least one of these compounds for use in the treatment of diseases or disorders in which kallikrein activity is dysregulated, particularly neurodegenerative and inflammatory diseases.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Goods & Services

Scientific apparatus and instruments; measuring apparatus and instruments; checking (monitoring) apparatus and instruments; sound transmitting apparatus; sound reproduction apparatus; image transmission apparatus; image reproduction apparatus; digital recording media; data processing equipment; smartphones; software (recorded programs); computer peripheral devices; integrated circuit cards [smart cards]; diagnostic apparatus not for medical use. Medical apparatus and instruments. Technical evaluations concerning design (engineers' services); scientific research; technical research services; software design; software development; research and development of new products for third parties; software development (design); software installation; maintenance of software; updating of software; software rental; programming for computers; electronic data storage. Medical services; medical assistance; hospital services; nursing homes; rehabilitation clinic services; rest home services.

Abstract

A nucleic acid for the controlled expression of a nucleic acid encoding a pro-apoptotic protein in an individual, including: a regulatory polynucleotide including a minimal promoter and at least one AARE (amino acid response element) nucleic acid, the regulatory polynucleotide being activated in an individual upon consumption of a diet deficient in at least one essential amino acid; and a nucleic acid encoding a pro-apoptotic protein, which is placed under the control of the regulatory polynucleotide.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A01K 67/027 - New or modified breeds of vertebrates
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

The invention relates to the treatment of a prion neurodegenerative disease by nasal administration of unloaded 2,6-di-O-methyl-beta-cyclodextrin (DIMEB).

IPC Classes  ?

• A61K 31/724 - Cyclodextrins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 47/02 - Inorganic compounds
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes

Abstract

The invention relates to compounds exhibiting kallikrein inhibitory activity, and to compositions comprising at least one of these compounds for use in the treatment of diseases or disorders in which kallikrein activity is dysregulated, particularly neurodegenerative and inflammatory diseases.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C07C 235/42 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
• C07C 235/58 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring

Abstract

Provided herein is a method for determining the temporal progression of a biological phenomenon which may affect a studied subject, the method including the steps of providing first data relative to biomarkers for the studied subject, the biomarkers being relative to the progression of the biological phenomenon, providing a numerical model, converting the first data into at least one point on the same Riemann manifold, and using a numerical model to determine a temporal progression for the biological phenomenon for the studied subject, the numerical model being a function in a Riemann manifold, the numerical model associating to values of biomarkers a temporal progression trajectory for the biological phenomenon and data relative to the dispersion of the progression trajectory for the biological phenomenon among a plurality of subjects, the numerical model being obtained by using a stochastic approximation in an expectation-maximization technique on data relative to biomarkers.

IPC Classes  ?

• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
• G06K 9/62 - Methods or arrangements for recognition using electronic means
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06T 7/00 - Image analysis

Goods & Services

Scientific apparatus and instruments; surveying apparatus and instruments; photographic apparatus and instruments; cinematographic cameras; optical apparatus and instruments; weighing apparatus and instruments; measuring apparatus and instruments; signaling apparatus and instruments; checking (supervision) apparatus and instruments; sound recording apparatus; sound transmitting apparatus; sound reproduction apparatus; image recording apparatus; image transmission apparatus; image reproduction apparatus; digital recording media; data processing equipment; computers; electronic tablets; smartphones; electronic book readers; game software; software (recorded programs); computer peripheral devices; detectors; electric wires; electric relays; clothing for protection against accidents, irradiation and fire; spectacles (optics); 3D spectacles; virtual reality helmets; optical goods; integrated circuit cards [smart cards]; smartwatches; electric batteries. Technical evaluations concerning design (engineers' services); scientific research; technical research; design of computers for others; software design; software development; research and development of new products for others; conducting of technical project studies; software development (design); software installation; software maintenance; updating of software; software rental; programming for computers; computer system analysis; computer system design; services provided by consultants relating to computer hardware design and development; digitization of documents; software as a service (SaaS); cloud computing; hosting of servers; vehicle roadworthiness testing; electronic data storage. Medical services; veterinary services; skin care services (beauty and sanitary care); medical assistance; hospital services; nursing homes; rehabilitation clinic services; rest home services; opticians' services; alternative medicine services.

Abstract

The present invention relates to a compound of formula (I) below: (I) or a pharmaceutically acceptable salt and/or solvate thereof, in particular as catechol-O-methyl transferase (COMT) inhibitor. The present invention also relates to a pharmaceutical composition containing such a compound and to a method for preparing such a compound.

IPC Classes  ?

• C07D 217/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The invention relates to a method for determining the temporal progression of a biological phenomenon which may affect a studied subject, the method comprising the steps of providing first data relative to biomarkers for the studied subject, the biomarkers being relative to the progression of the biological phenomenon, providing a numerical model, converting the first data into at least one point on the same Riemann manifold, and using a numerical model to determine a temporal progression for the biological phenomenon for the studied subject, the numerical model being a function in a Riemann manifold, the numerical model associating to values of biomarkers a temporal progression trajectory for the biological phenomenon and data relative to the dispersion of the progression trajectory for the biological phenomenon among a plurality of subjects, the numerical model being obtained by using a stochastic approximation in an expectation- maximization technique on data relative to biomarkers taken at different time points for a plurality of subjects.

IPC Classes  ?

• G06K 9/62 - Methods or arrangements for recognition using electronic means

Abstract

The invention relates to age-related brain diseases, such as Parkinson's or Alzheimer's disease. Statistical models based on the regression of measurements with age are inadequate to model the progression of such diseases. As a consequence, the inventors worked on a numerical model to determine a temporal progression for such biological phenomenon, the numerical model being a function in a Riemann manifold. Such model enables to obtain a method for determining the temporal progression of a biological phenomenon which can be implemented on computer and provides better results than statistical models based on the regression of measurements. This determining method may be applied for predicting that a subject is at risk of suffering from such disease, diagnosing a disease, identifying a therapeutic or a biomarker and screening compounds useful as a medicine.

IPC Classes  ?

• G06K 9/62 - Methods or arrangements for recognition using electronic means

Abstract

The invention relates to compounds of formula (I), particularly for the use thereof as a medicament, especially in the treatment or prevention of neurogenerative disorders. The invention also relates to the methods for producing said compounds, and to the pharmaceutical compositions containing same. La présente invention concernedes composés de formule (I) suivante: en particulier pour leur utilisation en tant que médicament, notamment dans le traitement ou la prévention de maladies neurodégénératives,ainsi que leurs procédés de préparation et les compositions pharmaceutiques les comprenant.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention concerns the field of methods for in vitro diagnosis of Alzheimer's disease in a human subject. The invention concerns a method for in vitro diagnosis of Alzheimer's disease in a human subject, characterised in that it comprises the analysis of DYRK1A in a blood and/or plasma and/or serum sample from said subject. Preferably, the analysis of DYRK1A comprises determining the level of expression of DYRK1A. According to one embodiment, the method of the invention is characterised in that said subject has Alzheimer's disease if said level of expression of DYRK1A is lower than a reference level of expression of DYRK1A. According to a specific embodiment, the method of the invention further comprises determining the level of expression of at least one of the markers chosen from homocysteine, BDNF and APOD in a blood and/or plasma and/or serum sample from said subject.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Goods & Services

Pharmaceutical products, compounds for the treatment of diseases and degenerative conditions of the brain and the spinal cord; sanitary preparations for medical use; dietetic substances adapted for medical use; adjuvants for medical use; chemical pharmaceuticals; chemical preparations for medical or pharmaceutical use; products for diagnostic purposes for medical use; medicines for human purposes. Surgical, medical apparatus and instruments, for the prevention, treatment and repair of damage caused by diseases of the brain and the spinal cord; orthopedic articles; apparatus for use in medical analysis. Paper, cardboard and goods made from these materials, not included in other classes; printed matter; bookbinding material; photographs; stationery; instructional and teaching material (except apparatus); printing blocks; posters; albums; almanacs; pamphlets; circulars; books; booklets; manuals; periodicals; photographs; prospectuses; publications; graphic representations; graphic reproductions; journals. Therapeutic education; training in the field of neurology; organization and conducting of colloquiums, conferences, congresses, seminars, symposiums; drafting and publishing of books and texts other than for advertising purposes; publication of electronic books and journals online; organization of exhibitions for cultural or educational purposes; entertainment; organization of competitions; organization of sporting events. Scientific and technological services and research and design relating thereto; scientific research and development services for the preservation and treatment of diseases or degenerative conditions of the brain and of the spinal cord and to increase neurological capacity; procedures and techniques for treating brain and spinal cord diseases and for increasing neurological capacity; analysis services in the field of medicine and health; academic research; clinical trials; analysis and simulation of neurological functions. Medical and health services; nursing services; hospital services; rest homes; medical clinic services; surgical treatment of the brain and spinal cord; bone marrow transplantation; hygienic care; prophylactic services for improving, maintaining and treating the brain and spinal cord, rehabilitation and management of disabilities.

Goods & Services

Pharmaceutical preparations, compositions for the treatment of pathologies in or degeneration of the brain and spinal cord; sanitary preparations for medical purposes; dietetic substances adapted for medical use; adjuvants for medical purposes; chemical-pharmaceutical preparations; chemical preparations for medical or pharmaceutical use; diagnostic products for medical use; medicines for human purposes. Surgical, medical apparatus and instruments, for the prevention, treatment and repair of diseases of the brain and spinal cord; orthopaedic articles; apparatus for use in medical analysis. Paper, cardboard and goods made of these materials, not included in other classes; printed matter; bookbinding material; photographs; stationery; instructional or teaching material (except apparatus); printing blocks; posters; scrapbooks; almanacs; pamphlets; newsletters; books; booklets; manuals; periodicals; photographs; prospectuses; printed publications; graphic representations; graphic reproductions; reviews. Therapeutic education; training in the field of neurology; organization and conducting of colloquiums, conferences, congresses, seminars, symposiums; drafting and publishing of books and texts other than for advertising purposes; electronic publishing of books and periodicals online; organization of exhibitions for cultural or educational purposes; entertainment; organization of competitions; organization of sports events. Scientific and technological services and research and design relating thereto; scientific research and development services for preserving and treating pathologies in or degeneration of the brain and spinal cord and for increasing neurological ability; design and development of procedures and techniques for treating brain and spinal cord pathologies and for increasing neurological abilities; analysis services in the field of medicine and health; academic research; clinical trials; analysis and simulation of neurological functions. Medical and health services; nursing services; hospital services; convalescent homes; medical clinic services; surgical treatment of the brain and spinal cord; bone marrow transplantation; sanitary care; prophylactic services for improving, maintaining and treating the brain and spinal cord, rehabilitation and care for handicaps.

Goods & Services

Pharmaceutical preparations, compositions for the treatment of pathologies in or degeneration of the brain and spinal cord; sanitary preparations for medical purposes; dietetic substances adapted for medical use; adjuvants for medical purposes; chemical-pharmaceutical preparations; chemical preparations for medical or pharmaceutical use; diagnostic products for medical use; medicines for human purposes. Surgical, medical apparatus and instruments, for the prevention, treatment and repair of diseases of the brain and spinal cord; orthopaedic articles; apparatus for use in medical analysis. Paper, cardboard and goods made of these materials, not included in other classes; printed matter; bookbinding material; photographs; stationery; instructional or teaching material (except apparatus); printing blocks; posters; scrapbooks; almanacs; pamphlets; newsletters; books; booklets; manuals; periodicals; photographs; prospectuses; printed publications; graphic representations; graphic reproductions; reviews. Therapeutic education; training in the field of neurology; organization and conducting of colloquiums, conferences, congresses, seminars, symposiums; drafting and publishing of books and texts other than for advertising purposes; electronic publishing of books and periodicals online; organization of exhibitions for cultural or educational purposes; entertainment; organization of competitions; organization of sports events. Scientific and technological services and research and design relating thereto; scientific research and development services for preserving and treating pathologies in or degeneration of the brain and spinal cord and for increasing neurological ability; design and development of procedures and techniques for treating brain and spinal cord pathologies and for increasing neurological abilities; analysis services in the field of medicine and health; academic research; clinical trials; analysis and simulation of neurological functions. Medical and health services; nursing services; hospital services; convalescent homes; medical clinic services; surgical treatment of the brain and spinal cord; bone marrow transplantation; sanitary care; prophylactic services for improving, maintaining and treating the brain and spinal cord, rehabilitation and care for handicaps.